ASHINGTON INNOVATION PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.275 GBX | 0.00% |
|
0.00% | -53.64% |
| 01-24 | MetalNRG's legal settlement; Impellam confirms payout | AN |
| 01-24 | Ashington Innovation Ends Merger Talks with Cell Therapy | MT |
Income Statement Evolution (Annual data)
| Fiscal Period: July | 2021 | 2022 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT 1 | -0.2097 | -0.3814 |
| Operating Margin | - | - |
| Earnings before Tax (EBT) 1 | -0.2097 | -0.3814 |
| Net income 1 | -0.2097 | -0.3814 |
| Net margin | - | - |
| EPS 2 | -0.009868 | -0.0111 |
| Free Cash Flow | - | -0.1866 |
| FCF margin | - | - |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share | - | - |
| Announcement Date | 22-02-21 | 23-01-31 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: July | 2021 | 2022 |
|---|---|---|
| Net Debt 1 | - | - |
| Net Cash position 1 | 0.07 | 0.14 |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow | - | -0.19 |
| ROE (net income / shareholders' equity) | - | -3,987% |
| ROA (Net income/ Total Assets) | - | -222% |
| Assets 1 | - | 0.1716 |
| Book Value Per Share 2 | 0 | 0 |
| Cash Flow per Share 2 | 0 | 0 |
| Capex | - | - |
| Capex / Sales | - | - |
| Announcement Date | 22-02-21 | 23-01-31 |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -53.64% | 1.01M | |
| +58.06% | 4.89B | |
| +98.02% | 1.23B | |
| +2.71% | 988M | |
| +16.68% | 763M | |
| +2.11% | 666M | |
| +2.33% | 621M | |
| -.--% | 600M | |
| +10.56% | 537M | |
| -.--% | 500M |
- Stock Market
- Equities
- ASHI Stock
- Financials Ashington Innovation PLC
